Dive Brief:

Elevance has added a former Pfizer executive to its board, the latest addition of pharmaceutical industry veteran as the insurer focuses on building its pharmacy services.

Amy Schulman will start as an independent director of Elevance effective Jan. 12, the insurer announced Wednesday. Schulman will serve on the board’s audit and finance committees.

Schulman’s “insight into the intersection of science, technology, and patient care makes her an exceptional addition as we continue to advance and expand our services,” Ramey Peru, chair of Elevance’s board, said in a statement.

Dive Insight:

Elevance has been building up its board of directors, including through the addition of Steve Collis , a longtime drug distributor executive, in July.

Schulman’s appointment reflects

See Full Page